about
Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.Lipoprotein (a): a historical appraisal.Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Lipoprotein(a): A missing culprit in the management of athero-thrombosis?Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles.The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease.[Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns.Will you, nill you, I will treat you: the taming of lipoprotein(a).
P2860
Q37703242-76572730-8FBA-4ADA-AF68-C762670CC8BFQ38373582-78328018-6331-43AB-91E1-5E0B483958EDQ38966500-73D037DA-314E-4BDE-8921-FEB8B434540BQ38985774-333FC7B4-0A3B-4FC6-9BF2-6105734D8CCAQ39002143-85FB1A00-ACC4-4FBF-878B-28A1D1D586F8Q39148923-8A5BF9F0-2189-473B-B921-C39E0A51BB70Q39368804-43EAE418-E5FC-4963-91F2-73BC47B360A8Q40348492-4FF8F24A-19DC-4E92-B773-7CCB13917350Q46857725-104F7FA2-0F10-485E-9F2E-74FAB1F4A8B0Q47274864-51C10989-4AE3-434B-9606-2E2CB85B2C62Q47563984-F293C857-7F6C-422F-BE0D-E97C6E245725Q48746671-71312C6D-759C-457E-AF7E-51BB91ED68F3Q50081201-83368FE4-6385-4068-ACCC-6D8076255E85Q52641914-14092411-1C9D-45CE-AE8C-427DFE2B5836Q54737669-84188E07-4A96-4D2E-8417-81E7554FD508
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lipoprotein (a) measurements for clinical application.
@ast
Lipoprotein (a) measurements for clinical application.
@en
type
label
Lipoprotein (a) measurements for clinical application.
@ast
Lipoprotein (a) measurements for clinical application.
@en
prefLabel
Lipoprotein (a) measurements for clinical application.
@ast
Lipoprotein (a) measurements for clinical application.
@en
P2860
P356
P1476
Lipoprotein (a) measurements for clinical application.
@en
P2093
John J Albers
Santica M Marcovina
P2860
P304
P356
10.1194/JLR.R061648
P577
2015-12-04T00:00:00Z